Table 1 EZH2 staining pattern in HB relative to histopathologic subtype in tumor.
From: Investigating the oncogenic role of aberrant EZH2 in hepatoblastoma
H&E | EZH2 | ||
|---|---|---|---|
Case | Histologic patterns | Staining by histologic pattern | Overall staining pattern |
24 | HCC-like | 0 | 0 |
25 | Cartilage | 0 | 0 |
27 | CF, rare multinucleated and pleo, B, pseudoacinar, possible melanin | 3 + (unclear which histologic pattern) | 3 + < 5% |
28 | Bone, cartilage | 1 + bone and cartilage | 1 + < 5% |
30 | CF, E, B, rare pleo | 1 + E, 1 + CF | 1 + 10% |
38 | CF, B, cholangio | 2–3 + B/cholangio, 2 + CF | 1 + 10%; 2 + 70%; 3 + 20% |
41 | CF, E, B | 3 + B/E, 1–2 + CF | 1–2 + 30%; 3 + 70% |
42 | HCC-like (pleo, steatosis) | 1–3 + | 1 + 10%; 2 + 50–60%; 3 + 30% |
48 | Fetal-like, macro, mild pleomorphism | 2–3 + | 2 + 10–15%; 3 + 10–15% |
50 | CF, B, osteoid | 2 + CF, 0 osteoid | 2 + < 5% |
52 | HCC | 1–3 + | 1 + 50%; 2 + 20%; 3 + 20% |
53 | CF, E, B | 1 + E | 1 + 5–10% |
64 | Osteoid | 3 + osteoid | 3 + 100% |
69 | CF | 1 + CF | 1 + < 5% |
74 | CF, E, B, mild pleo | 2–3 + E | 2 + 5–10%; 3 + 5–10% |
79 | HCC | 1–3 + | 1 + < 5%; 2 + < 5%; 3 + < 5% |
81 | CF, E | 3 + E, 0–2 + CF | 0–1 + 5%; 2 + 5%; 3 + 90% |
84 | HCC | 1–3 + | 1 + < 5%; 2 + < 5%; 3 + 90% |
105 | HCC (difficult to tell border of background from tumor) | 1–3 + | 1 + < 5%; 2 + < 5%; 3 + < 5% |
